Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Jun 5, 2017 -- Oral presentations highlighted data from plazomicin Phase 3 EPIC and CARE clinical trials -- -- Newly-released in vitro data demonstrated potent activity of plazomicin against contemporary multidrug-resistant Enterobacteriaceae isolates -- NEW ORLEANS, June 05, 2017 (GLOBE NE...
Jun 1, 2017 -- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- -- Initiation of pivotal Phase 3 clinical trial in patients with compl...
May 31, 2017 SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the completion of its previously announced underwritten public ...
May 26, 2017 - Two oral presentations highlighting data from plazomicin Phase 3 EPIC and CARE clinical trials - - Eleven poster presentations highlighting plazomicin's activity against MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE) - SOUTH SAN FRANCISCO, ...
May 25, 2017 SOUTH SAN FRANCISCO, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an underwritten public offering of 5,000,000 share...
May 23, 2017 SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy desi...
May 23, 2017 SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of up to ...
May 8, 2017 -- Presented additional Phase 3 EPIC and CARE trial data highlighting the safety and efficacy of plazomicin during late-breaker session at ECCMID -- -- Plazomicin registration activities on track; NDA submission planned for the second half of 2017 -- -- Co...
May 5, 2017 The Bill & Melinda Gates Foundation is committing up to $20 million in grant funding and equity investment to further the development of an antibody platform and discovery of monoclonal antibody candidates against gram-negative bacteria, including those that cause neonatal sepsis Importa...
May 1, 2017 SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its first quarter 2017 financial results on Mo...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase